万基遗传 MYGN 深 沪
等待开盘 08-07 09:30:00 美东时间
3.07
-0.080
-2.54%
华盛通- 最 高3.21
- 今 开3.11
- 成交量 59.85万股
- 最 低 3.015
- 昨 收 3.15
- 总市值 2.94亿
- 52周最高 8.59
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 2.74
- 委 比 -5.88%
- 总股本 9564.96万
- 历史最高 50.44
- 量 比 0.20
- 振 幅 6.19%
- 历史最低 2.74
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
07-31 04:49
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
Myriad Genetics will hold its second quarter 2026 earnings conference call on July 30, 2026, at 4:30 pm ET. The company will release its quarterly earnings the same day after market close. Management will discuss financial results and business updates during the call. A live webcast and archived recording will be available on investor.myriad.com. Participants can register for the call via the provided link. Myriad Genetics is a leader in molecula...
07-23 13:05
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics announces that the Prolaris Biopsy Test provides significant prognostic information beyond conventional clinical risk categories for localized prostate cancer, as shown in a meta-analysis of 14 studies involving over 8,000 patients. The Prolaris combined clinical risk score (CCR) is prognostic for distant metastasis and prostate cancer-specific mortality across all risk groups, offering independent, additive prognostic value beyon...
07-02 13:05
Myriad Genetics Announces Expanded Availability Of Precise MRD To Patients Undergoing Treatment And Surveillance For Breast, Colorectal And Renal Cancers
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. More than 6 million indivi...
06-23 21:07
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics expanded Precise MRD availability for breast, colorectal, and renal cancers, benefiting over 6 million U.S. patients. Precise MRD, an ultrasensitive whole-genome sequencing test, tracks up to 1,000 variants for personalized cancer monitoring. The MONITOR-Breast study, published in *Future Oncology*, demonstrates its clinical validity, showing high ctDNA detection rates, accurate treatment response prediction, and improved risk str...
06-23 13:05
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics announced the launch of the Prolaris + AI Test, the first prostate cancer biomarker test combining clinical-pathological features, a molecular score, and AI-powered digital pathology. This integration helps clinicians determine if patients are suitable for active surveillance (AS) and personalize AS intensity. The AI technology analyzes biopsy images to predict Gleason score upgrades, providing insights beyond traditional tools. T...
05-26 20:05
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Netflix actress Jackie Tohn partners with Myriad Genetics to raise awareness about hereditary cancer testing. After discovering she carried a BRCA1 gene variant following her father's cancer diagnosis, Tohn underwent a prophylactic double mastectomy and plans for an oophorectomy. She emphasizes the importance of genetic testing, especially for those with a family history of cancer. Myriad's MyRisk® Hereditary Cancer Test evaluates 63 genes to ass...
05-15 15:00
